Halozyme Therapeutics Announces $1.05B Convertible Note Offering

What Happened

• Halozyme Therapeutics, Inc. (HALO) filed an 8-K on September 16, 2026 announcing it proposes to offer $1.05 billion aggregate principal amount of convertible senior notes due 2033. The company also expects to grant the initial purchasers a 13‑day option to buy up to an additional $150 million of the notes. The offering is subject to market conditions and other factors. The filing includes a press release attached as Exhibit 99.1 and was signed by Darren Snellgrove, EVP & CFO.

Key Details

• Proposed principal amount: $1.05 billion of convertible senior notes due 2033.
• Additional option: 13‑day option for initial purchasers to buy up to $150 million more.
• Filing date: Form 8‑K dated September 16, 2026; press release attached as Exhibit 99.1.
• Offering subject to market conditions and other customary factors (not yet completed).

Why It Matters

• This proposed debt offering would provide Halozyme with substantial capital, which can support R&D, operations, or other corporate needs (company did not specify uses in the 8‑K).
• Because the notes are convertible, they could convert into equity under their terms, potentially diluting current shareholders if conversions occur.
• The transaction will also affect Halozyme’s capital structure—adding long‑term debt obligations (maturity 2033) and potential future equity issuance—so investors should watch for finalized terms, interest rate, conversion price, and the company’s stated use of proceeds in subsequent filings.